Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
Bioenvision (BIVN) Oppenheimer Cory Kasimov New Buy
Kasimov set a $16 target. He expects the company's clofarabine cancer compound will be approved by year end. BIVN closed Friday at $9.80, up

Read the full 405 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE